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EPIDEMIOLOGY                                                                  
Heart failure (HF) is a major and growing public health problem in the 
United States. Overall incidence of congestive heart failure (CHF) 
approaches 10/1 000 after age of 65 (Framingham Heart Study data) 
and increases with increasing age. The disorder is the primary reason 
for 12 to 15 million offi ce visits and 6.5 million hospital days each year. 
In 2005 alone, the cost of management of heart failure was $ 27.9 
billion in the US.(1)
Though multiple clinical trials completed during the past 15 years have 
unequivocally shown a substantial reduction in mortality for patients 
with systolic heart failure, large epidemiologic surveys, such as the 
ongoing Framingham Study, have not documented any meaningful change 
in overall death rates. 80% of men and 70% of women under age 65 
who have CHF will die within 8 years.(1) This is in contrast to the average 
life expectancy of 19.2 years for women at age 65 and 16.3 years for 
men (2003 United Nations Economic Commission for Europe report).(2) 
From 1992-2002 deaths from heart failure increased by 35.3%, while in 
the same period the overall death rate increased by 7.7%.(2) 
PATHOPHYSIOLOGY OF HEART FAILURE                      
Various conceptual paradigms have been put forward to explain the 
clinical syndrome of heart failure. The mechanistic view of heart failure 
as failure to pump blood at a rate required by the metabolizing tissues, 
or ability to do so only with an elevated pressure, is only partially 
correct. Research in the past few decades has highlighted the importance 
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of activation of neurohumoral mechanisms, immune system, ventricular 
remodeling and development of renal changes, i.e. cardiorenal syndrome 
in the progression of disease. It is beyond the scope of this review to go 
over the details. Salient features to understand are that 1) heart failure 
is a systemic dynamic progressive disease process brought on by the 
interaction between the heart, kidneys, renin-angiotensin system, 
sympathetic nervous system, endothelium and immune system through 
intricate feedback loops, 2) development of cardiorenal syndrome – the 
spiral of worsening heart failure and kidney failure that leads to diuretic 
resistance, volume overload and refractory heart failure, and 3) volume 
overload plays a signifi cant role in pathophysiology of progressive heart 
failure apart from contributing to symptomatology.(3, 4)
MANAGEMENT OF VOLUME OVERLOAD IN HEART 
FAILURE
Insights into these pathophysological mechanisms has changed 
treatment of heart failure in the last two decades, with the introduction 
of beta blockers and angiotensin converting enzyme (ACE) inhibitors 
as the fi rst line of treatment and experimental therapies like anti-tumor 
necrosis factor (TNF) agent, anti-vasopressin and natriuretic peptides. 
It is not within the scope of this paper to go into the details of all the 
therapies for heart failure. We refer the readers to the American 
College of Cardiology 2005 guidelines.(5) We’ll only discuss problems 
with management of salt and water excretion in refractory heart failure, 
newer drugs and the place of peritoneal dialysis. The importance of salt 
and water management is borne out by the fact that 80% of CHF 
admissions are for acute decompensation. Most of these patients are 
admitted for fl uid overload and congestion rather than low perfusion. 
Only 5% of patients have low output at admission.(6) Unfortunately, 
diuretic-based strategies are not always effective in reducing edema. In 
ADHERE (The Acute Decompensated Heart failure National Registry), 
21% of patients admitted for decompensated heart failure were 
discharged without weight loss or with a gain in weight.(7)
Salt and water excretion is impaired early in patients with congestive 
heart failure because of the following reasons:
■  Low cardiac output leads to underfi lling and compensatory increase 
in sodium and water retention in proximal tubules.
■  Activation of Renin Angiotensin Aldosterone System(RAAS) causes 
sodium retention mediated by Angiotensin II (AT 2) through its 
action on Angiotensin 1 (AT1) receptor.
■  Release of aldosterone due to RAAS activation impairs distal 
tubular sodium excretion.
Authors: Abirami Krishnan, D.G. Oreopoulos
Heart failure is a major and growing health 
problem. There have been major advances in the understanding of 
pathophysiology of heart failure as a chronic progressive disorder, 
which has led to newer therapies. Whatever the etiology, many heart 
failure patients eventually progress to a refractory stage characterized 
by worsening renal function and resistance to diuretic therapy with 
attending severe edema. A logical treatment for this “cardiorenal 
syndrome” is the use of dialysis, which is effi cient in treating both the 
hypervolaemia and azotaemia of refractory heart failure. Though all 
modalities of dialysis have been tried, peritoneal dialysis (PD) is the 
simplest choice and offers several advantages. It is an already established 
long-term home-based therapy and does not require complex 
machinery or hospital resources. PD is associated with preservation of 
residual renal function, gentle continuous ultrafi ltration, hemodynamic 
stability, better middle molecule clearance, sodium seiving with 
maintenance of normonatremia and maybe less infl ammation, especially 
with newer solutions, compared to hemodialysis. In this paper we 
discuss the potential advantages of PD in the treatment of heart 
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■  Sympathetic activation leads to sodium and water retention 
indirectly, by activating the RAAS system and by decreasing the 
glomerular fi ltration rate (GFR) secondary to vasoconstriction.
■  Impairment of GFR mediated by various neurohormonal pathways; 
vasoactive molecules impair sodium and water excretion.
■  Activation of vasopressin impairs water excretion.
Moreover, heart failure patients with mild to moderate disease have a 
response that is only one-fourth to one-third of that normally observed 
with maximally effective doses of loop diuretics. The response in patients 
with more severe disease is smaller yet.(8) This is due to many of the 
factors described above, which cause salt and water retention apart 
from impaired absorption of oral drugs due to gastric congestion and 
increased proximal tubular absorption, with decreased delivery of 
fi ltrate to Thick Ascending Limb of Henle (TALH) and distal tubule 
where the traditional diuretics act. 
Apart from failure of therapy, there is concern of increased mortality 
with use of some classes of diuretics. SOLVD (Studies Of Left Venricular 
Dysfunction) database demonstrated that, compared with patients not 
taking any diuretic, the risk of hospitalization or death due to worsening 
heart failure in patients taking non-potassium sparing diuretics alone 
was signifi cantly increased (risk ratio – 1.31, 95% CI 1.09 to 1.57; 
p < 0.0004) and this was not observed in patients taking potassium 
sparing diuretics with or without a non-potassium sparing diuretic.(9) 
Hence the ongoing search for newer agents in the management of salt 
and water retention. As such, many of the current standard therapies 
for heart failure directly or indirectly infl uence sodium and water 
excretion like beta-blockers, ACE inhibitors, inotropes and aldosterone 
antagonists. Newer agents like vasopressin receptor antagonists 
(vaptans), natriuretic peptides and adenosine receptor antagonists 
being developed for the treatment of heart failure also promote salt 
and water excretion. Among these, vaptans are the only drugs which 
are closer to being used in routine clinical practice.
Vasopressin receptor antagonists
Development of vasopressin receptor antagonists was prompted by 
the realization that levels of arginine vasopressin are elevated in heart 
failure and are believed to result in 1) myocardial hypertrophy and 
vasoconstriction mediated by its action on V1a receptor causing 
vasoconstriction and increasing after load, and 2) water retention and 
hyponatremia mediated by its action on V2 receptor and thereby 
increases preload. Early trials have shown that therapy with vaptans 
signifi cantly reduces weight, corrects hyponatremia,(10) and reduces 
mortality.(11) These encouraging fi ndings have led to a large multi-center 
randomised double blind trial EVEREST (The Effi cacy of Vasopressin 
Antagonism in Heart Failure Outcome Study With Tolvaptan). In this 
trial, during a median follow-up of 9.9 months, there was no difference 
in overall mortality, cardiovascular mortality or hospitalization in the 
group treated with Tolvaptan as compared to placebo in addition to 
standard therapy. But Tolvaptan signifi cantly improved secondary end 
points of day 1 patient-assessed dyspnea, day 1 body weight, and day 7 
edema. In patients with hyponatremia, serum sodium levels signifi cantly 
increased.(12) 
Ultrafi ltration
The use of ultrafi ltration(UF) for CHF was reported as early as in 1979.(13) 
However, the need for bulky hemodialysis machines and central venous 
access made this treatment unpopular. Availability of a new peripheral 
veno venous hemofi ltration machine (system 100, CHF solutions) has 
brought this treatment into focus again. Costonza et al.(16) reported their 
experience in 20 patients with acute decompensated heart failure. This 
machine was used to ultrafi lter till the patients were relieved of congestive 
symptoms. On average, 8.6+ 4.2 L was removed. All patients had relief of 
all signs and symptoms of CHF and they remained symptom free till 90 
days. Treatment was not associated with deterioration in renal parmaeters 
or hypotension. However, the mean dose of diuretics used increased 
with admission and remained high after discharge. 
In another study Bart et al. (RAPID-CHF trial)(14) reported the results 
of a randomized but nonblinded trial of usual care versus usual care and 
UF in 40 patients admitted with acute decompensated heart failure and 
evidence of volume overload. Patients in the UF group received an 8-h 
UF treatment in addition to usual care; however, diuretics were withheld 
during UF. Dyspnea and CHF symptoms improved in both groups at 
24 hours, with a slightly greater improvement at 48 hours in the UF 
group. The average volume removal was higher in the UF group at 
24 hours (4.6 vs. 2.8 l) and 48 hours (8.4 vs. 5.3 l). However, weight loss, 
a surrogate marker of adequate diuresis and net fl uid loss, which was 
the primary endpoint of the study, was not signifi cantly different 
between groups. There was one death in the UF group during the 
30-day follow-up. Adverse events included catheter infection, which 
required a 4-week course of intravenous (IV) antibiotics, and there was 
a small but signifi cant drop in the hemoglobin in the treatment group, 
the opposite of what could be expected during aggressive diuresis. 
The Ultrafi ltration Versus IV Diuretics for Patients Hospitalized for 
Acute Decompensated Congestive Heart Failure (UNLOAD) trial 
compared the use of intravenous diuretics and ultrafi ltration in 200 
patients hospitalized for decompensated heart failure. Preliminary data 
were presented at the 2005 American College of cardiology meeting, 
and indicated that patients randomly assigned to receive ultrafi ltration 
lost more weight and, at 90 days, had a lower rate of rehospitalization. 
Incidence of hypotension was similiar in the two groups and ultrafi ltration 
did not seem to have an adverse effect on the renal function.(15)
Marenzi g et al.(17) studied the effect of ultrafi ltration on hemodynamics 
in 20 patients with refractory congestive heart failure. All patients 





fl uid removed was 4.88 l + 896ml. They found that mean right atrial, 
pulmonary artery and wedge pressures decreased and cardiac output 
and stroke volume increased during the procedure and all the changes 
persisted up to 24 hours after procedure.
Recently Gura et al.(18) have reported the development and animal trial 
of a new wearable ultrafi lterable continuous device. The device consists 
of a hollow fi ber fi lter,  a 9 volt battery-operated pulsatile blood pump, 
a micro pump for heparin infusion, and another micro pump to control 
ultrafi ltration rate. Blood fl ow used was 65 ml/min and the weight 
of the device is less than 2.5 lb. Fluid removal rate ranged from 0 to 
700 ml/h and averaged 106 ml/h. 
This treatment modality is still in its infancy. Lots of questions still remain 
unanswered, such as: 1) Are there mortality and morbidity benefi ts? 
2) Who are the patients that are likely to benefi t and at what cost? 
3) Are the benefi ts sustained? 4) Does it alter the cardiorenal syndrome 
or worsen it? 5) Does it alter the pathophysiology of heart failure?
PERITONEAL DIALYSIS                                                      
In refractory heart failure the predominant pathophysiology is sodium 
and fl uid retention, and azotemia due to renal hypoperfusion with 
inadequate response to traditional medical therapy. A logical treatment 
for this “cardiorenal syndrome” is the use of dialysis, which is effi cient in 
treating both the hypervolemia and azotemia of refractory heart failure. 
Though all modalities of dialysis have been tried, PD is the simplest 
choice and offers several advantages. It is an already established long-
term home-based therapy and does not require complex machinery or 
hospital resources. PD is associated with preservation of residual renal 
function, gentle continuous ultrafi ltration, hemodynamic stability, better 
middle molecule clearance, sodium seiving with maintenance of 
normonatremia and maybe less infl ammation, especially with newer 
solutions compared to hemodialysis.
Clearance of middle molecules could be of importance. Various 
cytokines and humoral factors such as TNF, IL-1, reactive oxygen 
species(ROS), nitric oxide, vasopressin, angiotensin 2 and aldosterone 
have been implicated in the progression of heart failure. The molecular 
weight of these substances ranges between 500 and 30 000 dalton, 
which can be removed by PD. Zemel et al.(19) have shown the appearance 
of TNF alpha, soluble TNF receptor 1 and 2 in the PD effl uent.
Hyponatremia is a marker for poor outcome in heart failure. Among 
heart failure patients treated with angiotensin-converting enzyme 
(ACE) inhibitors, diuretics and beta-blockers, even a small decline in 
serum sodium levels, to 136 mEq/L or less, was associated with more 
than twice the risk of 60-day mortality and a signifi cant increase in risk 
of readmission or death within 60 days compared with serum sodium 
levels greater than 136 mEq/L.(20) In a study of patients with end-stage 
heart failure, Licata G et al.,(21) attempted to isolate the effect of an 
increase in serum sodium on clinical outcome. They randomized 107 
patients with refractory heart failure to receive an IV infusion of 
furosemide plus hypertonic 3% saline solution or an IV bolus of 
furosemide twice a day without hypertonic saline. Survival over a mean 
follow-up of 31 months was 55% in the group that received hypertonic 
saline compared with 13% in those that did not receive hypertonic 
saline (P < .001). This suggests that normalization of a low serum 
sodium by sodium seiving may be another potential mechanism of 
benefi t for PD.
Renal insuffi ciency signifi cantly increases the risk of death and thus is an 
important prognostic indicator in heart failure patients. Hillege et al.(22) 
reported in the Second Prospective Randomized Study of Ibopamine 
on Mortality and Effi cacy (PRIME-2) that patients with GFRs in the 
lowest quartile (< 44 mL/minute) had almost a three times higher risk 
of mortality than those in the highest quartile (GFR > 76; relative risk 
2.85, P < .0001). Impaired renal function was a stronger predictor of 
death in these patients with heart failure than a low ejection fraction. 
Forman et al.(23) found that heart failure patients whose renal function 
worsened while in the hospital had longer stays, incurred higher hospital 
costs, were more likely to die in the hospital and, if they survived the 
hospitalization, were more likely to be readmitted. It is not very clear 
whether this is an association because patients with renal failure are 
more likely to have refractory heart failure or if preserved renal function 
protects from worsening heart failure due to less infl ammatory activation. 
PD again has an advantage by preserving residual renal function.
In 1949, Schneierson(24) published the fi rst case report using PD as a 
successful therapy in a patient with severe CHF. Since then there have 
been multiple case reports and small series. Review of use of PD in CHF 
can be divided into three periods – intermittent PD(IPD), continuous 
PD and newer soultions. During these three phases, not only the 
technology of PD has changed, but also treatment of CHF has changed.
Intermittent PD
In the 1960s many cases of acute CHF treated by PD have been 
reported, in total about 56 such patients. In summary these reports 
demonstrated fl uid removal rate of 67-568ml/hour with improvement 
in symptoms in most of the patients. Fluid removal was associated with 
an improvement in plasma volume(25) and hyponatremia.(26) But the 
effect on cardiac output was variable. Interestingly a signifi cant 
proportion of patients became diuretic responsive and their renal 
function improved. Shilo et al.(27) demonstrated signifi cant improvement 
in GFR as measured by creatinine and inulin clearance and also renal 
blood fl ow measured by PAH clearance in 9 patients with refractory 
CHF who underwent intermittent PD. But because of the acute and 
intermittent nature of the treatment provided, it did not change the 
long-term course of the disease. Patients with remediable disease like 
acute myocardial infarction or the ones who went for cardiac surgery 
benefi ted from the ultrafi ltration. Raja et al.(28) fi rst reported the use of 
repeated intermittent PD in a 59-year-old patient with refractory CHF. 
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The patient underwent a total of 8 treatments over a period of 2 years 
and eventually died in a car accident. But later reports were not so 
optimistic. Shapira et al.(29) reported repeated intermittent PD in 10 
patients with refractory CHF. Though all patients showed improvement 
in symptomatology, sodium levels, urine output and diuretic 
responsiveness, 50% of the patients died 99 to 354 days after their fi rst 
dialysis. 90% of their patients also had gram negative bacteria cultured 
from their PD fl uid but none of the patients developed peritonitis. 
Another major limitation of this therapy was requirement of frequent 
hospitalization for the procedure.
Continuous PD
Despite the initial disappointment with IPD in the long-term 
management of heart failure, it was clear that Continuous PD (CAPD), 
because of its continuous nature, will be more appropriate. There are 
multiple case series on the use of CAPD and we summarise the major 
trials in the Table I. (NO TABLE SUPPLIED)
As we can see from the table, all patients show symptomatic improvement 
while on PD. Hospitalisation rate was decreased in all studies except the 
one reported by Rubin et al.(33) In their study patients were hospitalized 
as often for PD-related problems as for cardiac problems. Peritonitis 
rates were high in the earlier studies, which is not the problem with the 
newer connecting devices and automated devices. 
Though all patients showed symptomatic improvement, mortality 
remained high. It is not clear whether better volume management will 
translate to delay in progression of heart failure. There was no 
correlation between functional improvement and LV function as 
measured by left ventricular ejection fraction (LVEF).(31) But Stegmayr et 
al.(35) have shown reduction in CT index and Gotloib et al.(39) in their 
study found an improvement in the cardiac work index. Long-term 
follow-up studies are required to see the effect on progression. 
Though mortality was high in most of the studies, survival seems to be 
improving in the recent trials. Stegmayr et al.(35) studied patients with 
expected survival of 1 month and showed a signifi cant prolonged survival 
from 1 month up to 1 year. In the study by Gotloib et al.(39) they found 
a 1-year mortality rate of 10%, which was signifi cantly less than the 80% 
expected based on their charles comorbidity index. It is diffi cult to 
interpret these mortality data because none of these trials compared 
PD to standard care of therapy. It will be not be possible to do such a 
trial in patients with refractory heart failure and, for that matter, cardiac 
transplantation has never been compared either. It is also diffi cult to 
interpret whether this improvement is because of PD or overall improved 
management and survival in CHF patients with newer therapies. 
It is also interesting to note that in the trial by Ryckelynck et al.(36) 
two patients who were earlier rejected for cardiac transplant were 
found to be fi t and got transplanted after starting PD. In the trial by 
Konig et al.(34) three patients had cardiac transplantation after starting 
PD. PD could be afforded to patients waiting for cardiac transplant as 
bridge therapy.
Newer PD solutions
Even in renal failure patients on PD, introduction of icodextrin has been 
shown to decrease extra cellular water and improve hemodynamics. 
Icodextrin offers several advantages:
■  It offers more physiologic ultrafi ltration.
■  Euvolemia can be maintained without additional dextrose exchanges.
■  Single exchange is easy on lifestyle and decreases risk of touch 
contamination and hence incidence of peritonitis.
■  Avoidance of dextrose solutions could mean less peritoneal infl am-
mation. The effect of such infl ammatory markers in the progression 
of heart disease is not known.
Konings et al.(41) randomised 40 CAPD/CCPD patients (renal failure 
patients on dialysis) to either icodextrin during long dwell or standard 
glucose solution and found that use of icodextrin was associated with 
increased ultrafi ltration, lower extracelluar water as estimated by 
bromide dilution method. At the end of 4-month follow-up period they 
were also found to have signifi cantly lower LV mass. There are only a 
few case reports on the use of icodextrin in treatment of refractory 
CHF. Bertoli et al.(42) reported the use of a single 12-hour nighttime 
manual CAPD exchange with icodextrin in 2 non-uremic elderly 
patients with NYHA class 3-4 failure. They had daily ultrafi ltration of 
500-1 000 ml. Both patients showed improvement in their NYHA class, 
ejection fraction after 12 –15 months on PD. Urine output declined 
modestly in one patient, but renal function measured as creatinine 
clearance by the Cockroft-Gault method improved in both the patients. 
Neither of the patients required hospitalization for either cardiac or 
dialysis related issues, as compared to multiple admissions in the 
preceding year. 
FUTURE PROSPECTS                                                        
■  Comparison of PD versus standard therapy and ultrafi ltration 
devices to demonstrate survival benefi t with less morbidity and 
costs.
■  Is there preservation of renal function with PD as compared to 
standard medical therapy? Will this delay the progression of heart 
failure by interrupting cardiorenal syndrome?
■  What will be the effect of biocompatible PD solution with 
associated less infl ammation on heart failure pathogenesis?
■  Large trials with long-term follow-up looking at the effect of PD on 
progression of heart failure.
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